This activation was associated with an increased expression of inflammatory cytokines and subsequent enrichment of cancer stem cells (CSCs), all of which indicate that IRAK1 contributes to acquired resistance to paclitaxel treatment. The gene discussed is IRAK1; the disease is cancer.